TP53 and urinary bladder carcinoma: Third, in specific therapeutic contexts such as cisplatin-resistant bladder cancer, HF inhibits casein kinase 2, which normally phosphorylates oncogenic substrates including AKT, STAT3, and NF-κB, thus representing an alternative mechanistic entry point for p53-deficient malignancies [72].